Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial.

PURPOSE: To compare interferon (IFN) beta with methotrexate (MTX) in the treatment of intermediate uveitis with macular edema. DESIGN: Monocentric, prospective, randomized, controlled clinical trial. SETTING: Specialized uveitis center at the University of Heidelberg. PATIENT OR STUDY POPULATION: Patients with either primary intermediate uveitis or uveitis associated with multiple sclerosis. MAIN INCLUSION CRITERIA: Visual acuity of 20/30 or worse (0.2 logarithm of the minimal angle of resolution) and macular edema of more than 250 µm (central 1-mm in optical coherence tomography; Stratus). Randomization into either IFN beta 44 µg subcutaneously 3 times weekly or 20 mg MTX subcutaneously once weekly. MAIN OUTCOME MEASURES: At 3 months, the primary outcome parameter of mean change in visual acuity was evaluated and efficacy was determined. Secondary parameters were macular edema by optical coherence tomography, inflammatory activity, and retinal sensitivity by microperimetry (MP-1; Nidek). In case of treatment failure, switching to the other treatment arm was possible. RESULTS: Nineteen patients were included. Ten were randomized to MTX, and 9 were randomized to IFN beta. At 3 months, visual acuity improved a mean 0.31 logarithm of the minimal angle of resolution (range, -0.02 to -0.96, 15.6 letters on the Early Treatment Diabetic Retinopathy Study chart) in the IFN beta group versus a mean 0.09 logarithm of the minimal angle of resolution (range, 0.12 to -0.38, 4.7 letters) in the MTX arm (P = .0435, Mann-Whitney U test). Macular thickness decreased by a mean of 206 µm (range, -41 to -416 µm) in the IFN arm, but increased by 47 µm (range, 108 to -28 µm) in the MTX group (P < .0001). CONCLUSIONS: Although the sample size is small, results of the trial support superiority of IFN beta over MTX in the treatment of macular edema in the setting of intermediate uveitis.

Willingness to pay for cataract surgery in post-operative cataract patients in rural Malawi.

BACKGROUND: In order to improve the sustainability of eye care programs including provision of surgical services, an understanding of a patient's capacity to contribute towards the costs relating to sight-restoring surgery is essential. Therefore, we investigated willingness to pay for cataract surgery in a hospital-based cross-sectional study in rural Malawi. METHODS: We interviewed consecutive patients following surgery for senile cataract at Nkhoma Eye Hospital, Malawi. Patients were asked about their willingness to pay for surgery (in local currency, Kwacha, as well as surrogates for money). We also collected data on socio-demographic variables and pre- and post-operative visual acuity (VA). RESULTS: A total of 212 participants were included (99.5% acceptance), of whom 82.0% were farmers. Mean age of participants was 68.2 years, and 89 (42.0%) were female. There were 136 (64.2%) who were willing to pay something. Median willingness to pay was 500 Kwacha (interquartile range 0-2,000; ~US$3.00, August 2011). Following adjustment for age, sex, family size and occupation, patients who were blind pre-operatively (pinhole-corrected VA<3/60) were less likely to pay something for surgery (odds ratio 0.44, 95% confidence interval 0.20-0.96, P = 0.038) compared to those with VA>6/60. CONCLUSION: In this setting where people are used to free services, the median monetary amount elderly patients were willing to pay for surgery is well below the actual cost of screening, transport, accommodation and surgery. Substantial cost recovery will require pre-operative involvement of family members, but might slow down current screening practices and also lower acceptance rates.

QuantiFERON TB-Gold--a new test strengthening long-suspected tuberculous involvement in serpiginous-like choroiditis.

PURPOSE: To obtain a diagnosis of tuberculosis in patients with a specific subset of uveitis, serpiginous-like choroiditis. This subset has been suspicious for tuberculous etiology in single case reports and old textbooks. DESIGN: Retrospective evaluation of a diagnostic test in a specific uveitis cohort. METHODS: QuantiFERON is an approved, antigen-specific test that utilizes synthetic peptides representing Mycobacterium tuberculosis proteins. After incubation, interferon gamma secreted by T lymphocytes in response to these antigens is measured. We used the test in 21 of 26 patients identified from our database with serpiginous-like choroiditis. Rates of QuantiFERON positivity were compared to a group of healthy hospital employees (n = 208), another group of healthy hospital workers after tuberculosis contact (n = 117), and a group of randomly tested patients with other uveitis forms (n = 45). RESULTS: Eleven of 21 serpiginous-like choroiditis patients (52%) were tested positive. The rate of QuantiFERON positivity in the healthy control groups was 8.7% and 0.9%, and 13% in the other uveitis subsets. Four of the QuantiFERON-positive serpiginous-like choroiditis patients were treated with standard anti-tuberculostatic therapy; three finished the course and improved. Seven patients are either stable without therapy (n = 4) or on low-dose prednisone (n = 3). CONCLUSIONS: QuantiFERON testing revealed a high number of positive patients, which indicates a tuberculous etiology in this uveitis subset. Whether bacterial activity or secondary immunologic processes are causative remains a matter of speculation.